The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...

For just under $10 a month, Fair Value gives investors an edge by cutting through the noise and highlighting where ...

According to InvestingPro, Gilead maintains a "GREAT" financial health score and is a prominent player in the Biotechnology industry. The ASCENT-04 trial results showed that Trodelvy, when ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...